Beijing QL Biopharmaceutical registers 210-person semaglutide-to-zovaglutide switch trial
A 210-person Phase 2 trial would test whether adults with obesity can move from semaglutide to an experimental once-monthly GLP-1, but it has not started enrolling.
Beijing QL Biopharmaceutical has registered a Phase 2 trial that will test how adults with obesity tolerate a switch from semaglutide to the company's experimental drug zovaglutide, according to a change log that tracks edits to ClinicalTrials.gov records [1]. The study, HORIZON-SWITCH-SZ, is listed as not yet recruiting with 210 planned participants [1].
The registration was recorded on September 10, 2026, under the identifier NCT07812597 [1]. The title describes the study's purpose as evaluating the safety and tolerability of switching from semaglutide to zovaglutide in adults with obesity, and the sponsor is listed as Beijing QL Biopharmaceutical Co., Ltd. [1] Zovaglutide is a once-monthly GLP-1 peptide that is already in Phase 3 testing in China, and more than $72 million has been raised around the program [1].
The registry record does not include a start date, a completion date, the number or location of study sites, or details on how dosing will be handled during the switch [1]. No results have been posted [1].
QL Biopharmaceutical is not alone in testing a switch. The same change log recorded a Novo Nordisk Phase 3 study four days later, on September 14, 2026, that looks at how people with type 2 diabetes tolerate moving from semaglutide to CagriSema; that trial is also listed as not yet recruiting, also with 210 planned participants [1]. The change log keeps the previous value of each registry field when a sponsor updates a record, so the date a study first appears and the date its details change are both visible [1].
Obesity drug programs have been one of the areas drawing large private financing rounds, with investors paying for better dosing, tolerability and mechanisms, and with capital favoring companies that can reach a clinical result quickly [2]. Licensing clinical-stage assets from Chinese companies has become a common way for Western developers to skip years of discovery work and spend early funding on development instead [2].
Why it matters for patients
Switching from one GLP-1 medicine to another is a practical question patients raise, and this trial is designed to produce data on it rather than an answer that already exists. The registry entry names safety and tolerability, not weight change, as the focus of the study, and it does not list which side effects will be tracked or how long participants will be followed [1]. Whether a switch causes symptoms, requires a dose adjustment, or affects weight has not been reported for this drug [1].
For US patients, zovaglutide is not an approved medicine, and the trial is sponsored by a Chinese company [1]. Even a positive result from a 210-person Phase 2 study would not by itself make the drug available in the United States; US approval would require separate testing and review, and no US trial of zovaglutide has been reported [1].
The two registrations also show what competition among GLP-1 developers currently looks like. Companies with longer-interval candidates are registering studies that start with patients already taking semaglutide, the drug sold as Ozempic, Wegovy and Rybelsus, rather than with people who have never used an incretin [1].
What happens next
HORIZON-SWITCH-SZ is listed as not yet recruiting, and no start or completion date appears in the change log entry [1]. The next visible step would be a status change to recruiting and, later, a results posting [1]. Novo Nordisk's switching study is at the same stage, also listed as not yet recruiting [1]. No results from either study have been posted [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.